[go: up one dir, main page]

DE60316454D1 - Verfahren und dosierformen für die kontrollierte abgabe von paliperidon - Google Patents

Verfahren und dosierformen für die kontrollierte abgabe von paliperidon

Info

Publication number
DE60316454D1
DE60316454D1 DE60316454T DE60316454T DE60316454D1 DE 60316454 D1 DE60316454 D1 DE 60316454D1 DE 60316454 T DE60316454 T DE 60316454T DE 60316454 T DE60316454 T DE 60316454T DE 60316454 D1 DE60316454 D1 DE 60316454D1
Authority
DE
Germany
Prior art keywords
paliperidone
forming
controlled delivery
delivery
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60316454T
Other languages
English (en)
Other versions
DE60316454T2 (de
Inventor
Noymi V Yam
Iran Reyes
Nipun Davar
Atul D Ayer
Julie Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60316454(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE60316454D1 publication Critical patent/DE60316454D1/de
Publication of DE60316454T2 publication Critical patent/DE60316454T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60316454T 2002-07-29 2003-07-28 Verfahren und dosierformen für die kontrollierte abgabe von paliperidon Expired - Lifetime DE60316454T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US399590P 2002-07-29
US40600502P 2002-08-26 2002-08-26
US406005P 2002-08-26
PCT/US2003/023433 WO2004010981A1 (en) 2002-07-29 2003-07-28 Methods and dosage forms for controlled delivery of paliperidone

Publications (2)

Publication Number Publication Date
DE60316454D1 true DE60316454D1 (de) 2007-10-31
DE60316454T2 DE60316454T2 (de) 2008-06-26

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316454T Expired - Lifetime DE60316454T2 (de) 2002-07-29 2003-07-28 Verfahren und dosierformen für die kontrollierte abgabe von paliperidon

Country Status (28)

Country Link
US (1) US20040092534A1 (de)
EP (1) EP1539115B1 (de)
JP (1) JP4500679B2 (de)
KR (1) KR100699516B1 (de)
CN (1) CN1684670A (de)
AR (1) AR040721A1 (de)
AT (1) ATE373472T1 (de)
AU (1) AU2003256844A1 (de)
BR (1) BR0313139A (de)
CA (1) CA2494234C (de)
CO (1) CO5580742A2 (de)
CY (1) CY1107096T1 (de)
DE (1) DE60316454T2 (de)
DK (1) DK1539115T3 (de)
ES (1) ES2293039T3 (de)
HR (1) HRP20050077B1 (de)
IL (1) IL166489A (de)
MX (1) MXPA05001191A (de)
MY (1) MY137049A (de)
NO (1) NO324821B1 (de)
NZ (1) NZ570198A (de)
PE (1) PE20040132A1 (de)
PL (1) PL210119B1 (de)
PT (1) PT1539115E (de)
RU (1) RU2321391C2 (de)
TW (1) TWI363637B (de)
WO (1) WO2004010981A1 (de)
ZA (1) ZA200501641B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2005271522B2 (en) * 2004-08-04 2011-02-10 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
JP2009507774A (ja) * 2005-08-04 2009-02-26 アルザ・コーポレーシヨン 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物
WO2007081736A1 (en) * 2006-01-06 2007-07-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
PL3542792T3 (pl) 2007-04-25 2023-11-20 Eirgen Pharma Ltd. 25-hydroksywitamina d o kontrolowanym uwalnianiu
EP3225243B1 (de) * 2007-04-25 2025-09-03 Opko Renal, LLC Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus für chronische nierenerkrankung
PL2079446T3 (pl) * 2007-08-21 2012-04-30 Teva Pharma Preparat paliperidonu o przedłużonym uwalnianiu
BRPI0817946A2 (pt) 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
EP3909585A1 (de) * 2007-12-19 2021-11-17 Janssen Pharmaceutica NV Dosierplan im zusammenhang mit langwirkenden injizierbaren paliperidonestern
EP2280967A2 (de) * 2008-03-27 2011-02-09 Actavis Group PTC EHF Hochreines paliperidon oder ein pharmazeutisch unbedenkliches salz davon, welches im wesentlichen frei von keto-verunreinigungen ist
EP2326312A1 (de) * 2008-07-25 2011-06-01 KRKA, D.D., Novo Mesto Paliperidon-zusammensetzung mit festen matrixteilchen
EP2161019A1 (de) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Verlängerte Freisetzung von einer pharmazeutischen Mehrteilchenzusammensetzung mit Paliperidon
WO2010044097A2 (en) 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
CA2739181C (en) * 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
CA2777856A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
RS60087B1 (sr) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona
ES2602503T3 (es) 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US20120201886A1 (en) 2010-07-30 2012-08-09 Micro Labs Limited Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
US20150080404A1 (en) 2012-04-14 2015-03-19 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
KR102692169B1 (ko) 2013-12-03 2024-08-05 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
ES2961843T3 (es) 2014-04-04 2024-03-14 Intra Cellular Therapies Inc Gamma-carbolinas condensadas con heterociclo deuteradas como antagonistas de los receptores de 5-HT2A
CN106456638A (zh) 2014-04-04 2017-02-22 细胞内治疗公司 有机化合物
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
HUE053737T2 (hu) 2016-01-26 2021-07-28 Intra Cellular Therapies Inc Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
KR102483124B1 (ko) 2016-03-25 2022-12-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AU2017253821B2 (en) 2016-03-28 2022-11-03 Opko Ireland Global Holdings, Limited Methods of vitamin D treatment
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017174096A1 (en) 2016-04-05 2017-10-12 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018098115A1 (en) * 2016-11-23 2018-05-31 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP7132939B2 (ja) 2017-03-24 2022-09-07 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規組成物および方法
AU2018307479B2 (en) 2017-07-26 2024-06-20 Intra-Cellular Therapies, Inc. Organic compounds
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
BR112020019181A2 (pt) 2018-03-23 2021-01-05 Intra-Cellular Therapies, Inc. Compostos orgânicos
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
US10695345B2 (en) 2018-08-31 2020-06-30 Intra-Cellular Therapies, Inc. Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
KR102906995B1 (ko) 2018-08-31 2025-12-31 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
EP3993798A4 (de) 2019-07-07 2023-04-26 Intra-Cellular Therapies, Inc. Neuartige verfahren
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
EP4329734A4 (de) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantierbare vorrichtung zur verzögerten freisetzung einer makromolekularen arzneimittelverbindung
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
US20230364009A1 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of an Antipsychotic
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN120417904A (zh) 2022-12-30 2025-08-01 细胞内治疗公司 作用于血清素5-HT2A受体的杂环稠合γ-咔啉
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EP1029538A3 (de) * 1993-09-28 2003-10-15 R.P. Scherer GmbH Herstellung von Weichgelatinekapseln
SK282231B6 (sk) * 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CA2263558A1 (en) * 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
WO1999062496A1 (en) * 1998-06-03 1999-12-09 Alza Corporation Methods and devices for providing prolonged drug therapy
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
DK1126853T3 (da) * 1998-11-02 2006-08-14 Alza Corp Kontrolleret levering af antidepressine midler
CA2354472C (en) * 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
WO2004010981A1 (en) 2004-02-05
CN1684670A (zh) 2005-10-19
DE60316454T2 (de) 2008-06-26
TW200418524A (en) 2004-10-01
NZ570198A (en) 2010-01-29
PT1539115E (pt) 2008-01-14
BR0313139A (pt) 2005-07-05
CA2494234C (en) 2009-10-27
IL166489A (en) 2014-01-30
IL166489A0 (en) 2006-01-15
PE20040132A1 (es) 2004-03-06
KR100699516B1 (ko) 2007-03-26
CY1107096T1 (el) 2012-10-24
JP2005535682A (ja) 2005-11-24
NO20050956L (no) 2005-04-27
NO324821B1 (no) 2007-12-10
ES2293039T3 (es) 2008-03-16
RU2321391C2 (ru) 2008-04-10
HRP20050077A2 (en) 2005-12-31
AU2003256844A1 (en) 2004-02-16
KR20050044895A (ko) 2005-05-13
RU2005102105A (ru) 2005-08-10
ATE373472T1 (de) 2007-10-15
PL210119B1 (pl) 2011-12-30
JP4500679B2 (ja) 2010-07-14
DK1539115T3 (da) 2008-01-28
EP1539115A1 (de) 2005-06-15
CO5580742A2 (es) 2005-11-30
TWI363637B (en) 2012-05-11
MXPA05001191A (es) 2005-09-12
EP1539115B1 (de) 2007-09-19
HRP20050077B1 (hr) 2013-11-22
US20040092534A1 (en) 2004-05-13
PL376258A1 (en) 2005-12-27
AR040721A1 (es) 2005-04-20
CA2494234A1 (en) 2004-02-05
ZA200501641B (en) 2005-08-31
HK1072559A1 (en) 2005-09-02
MY137049A (en) 2008-12-31

Similar Documents

Publication Publication Date Title
DE60316454D1 (de) Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
DE60324376D1 (de) Halbleiterbauelement und Verfahren zu dessen Herstellung
DE60325690D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE50212077D1 (de) Piezoelektrisches bauelement und verfahren zu dessen herstellung
DE60326628D1 (de) Dorn und verfahren zur herstellung von stents
DE50213224D1 (de) Induktives bauelement und verfahren zu seiner herstellung
DE602004021927D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE602004002195D1 (de) Verfahren und apparat für die ablauffolgesteuerung von paketen
DE60305105D1 (de) Aluminiumbeschichtetes Bauteil und Verfahren zu dessen Herstellung
DE60327225D1 (de) Aripiprazol-komplex-formulierung und verfahren
DE60239464D1 (de) Piezoelektrisches porzellan und verfahren zu seiner herstellung
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
DE60337036D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60303268D1 (de) Verfahren und Vorrichtung zur Herstellung von Microarrays
DE50214272D1 (de) Piezoelektrisches bauelement und verfahren zu dessen herstellung
DE50307832D1 (de) Schichtsystem und verfahren zu dessen herstellung
DE60239493D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60314817D1 (de) Gatewaykarte, Gatewayvorrichtung, Verfahren zur Steuerung der Gatewaykarte und Computerprodukt
DE60329744D1 (de) Aminosäurepulver und verfahren zu seiner herstellung
DE602004010241D1 (de) Mehrschichtprodukt und verfahren zu seiner herstellung
DE60236790D1 (de) Piezoelektrischer oszillator und verfahren zu seiner herstellung
EP1599904A4 (de) Laterale lubistorstruktur und verfahren
DE60233077D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60229488D1 (de) Piezoelektrisches Bauelement und Verfahren zu dessen Herstellung
DE60323689D1 (de) Schräg geschichtetes furniermaterial und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
8363 Opposition against the patent